Basit öğe kaydını göster

Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter

dc.contributor.authorElaidi, Reza-Thierry
dc.contributor.authorMassard, Christophe
dc.contributor.authorRouge, Thibault De La Motte
dc.contributor.authorOudard, Stephane
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorAngelergues, Antoine
dc.contributor.authorMaillet, Denis
dc.contributor.authorFlechon, Aude
dc.contributor.authorMercier, Florence
dc.contributor.authorGuillot, Aline
dc.contributor.authorLe Moulec, Sylvestre
dc.contributor.authorGravis, Gwenaelle
dc.contributor.authorBeuzeboc, Philippe
dc.date.accessioned2021-03-04T11:17:22Z
dc.date.available2021-03-04T11:17:22Z
dc.identifier.citationAngelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc P., Massard C., et al., "Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter", 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31
dc.identifier.othervv_1032021
dc.identifier.otherav_7191f928-6ece-4904-8da2-01c512c6204b
dc.identifier.urihttp://hdl.handle.net/20.500.12627/78203
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titlePrognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume31
dc.contributor.firstauthorID141597


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster